Sunday, April 23, 2017 2:29:18 PM
In my opinion this is what is going on in the back ground.
Doctors who just want to use a patients stem cells for treatment do not want stem cells treated as a drug by the FDA. (USRM types)
Mesoblast is big pharma with their generic line and does not want individual stem cell use to succeed. They are aligned with Harvard, big investors like merril lynch and goldman sacs, and the big institutions that like expensive double blind trials.
RMAT will hopefully bypass a lot of the burocratic non sense in a sane effective way. There is a lot of the established heath industry threatened by it.
Have to see how this all plays out. Looks like this is a front row seat.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM